ENTITY
Lupin

Lupin (LPC IN)

279
Analysis
Health Care • India
Lupin is an Indian multinational pharmaceutical company that develops, manufactures, and markets a diverse range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company specializes in therapeutic areas such as cardiovascular, anti-diabetic, respiratory, anti-infective, and women's health. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.
more
bullish•Lupin
•08 Aug 2025 06:06•Broker

Lupin Ltd - Strong Results Led by New Launches

A strong set of results: Lupin reported a robust performance for Q1FY26, with revenue of Rs 6,268 Cr, up 12% YoY and 10.6% QoQ, broadly in line...

Logo
269 Views
Share
bullish•Lupin
•17 May 2025 04:17•Broker

Lupin Ltd - Lupin’s Vision: Growth, Innovation, & Market Leadership

Reported revenue increased by 14% YoY, driven by solid growth in the India and US businesses, which rose 19% and 7% YoY, respectively.

Logo
450 Views
Share
bullish•Lupin
•14 Feb 2025 02:24•Broker

Lupin Ltd - Lupin’s Vision: Growth and Market Leadership

Reported revenue grew by 11% YoY, led by the India and US businesses, which grew by 11.9% and 12.3%, respectively, YoY, and the EMEA business,...

Logo
238 Views
Share
bullish•Lupin
•11 Nov 2024 23:14•Broker

LUPIN Ltd - Steady Outlook on Product Development; Maintain ADD

eported revenue grew by 12.6% YoY, led by the India business, which grew by 18.8% YoY, and the Asia-Pacific business, which grew by 30% YoY.

Logo
237 Views
Share
bullish•Lupin
•05 Nov 2024 06:51•Broker

Lupin: US and India on Steady Footing, Upgrade to ADD

We upgrade Lupin (LPC) to ADD from REDUCE with a revised TP of INR 2,440 (31x Q3FY27E, up from INR 1,950 at 28x Q1FY27E)

Logo
336 Views
Share
x